Prebiotics & Probiotics

The International Scientific Association for Probiotics and Prebiotics (ISAPP) — the field's standard-setting body — defines the two terms precisely, and the distinction matters because the evidence for each looks very different.

A prebiotic is, per ISAPP's 2017 consensus statement, "a substrate that is selectively utilized by host microorganisms conferring a health benefit" — in practice, a fermentable fiber (inulin, fructooligosaccharides/FOS, galactooligosaccharides/GOS, resistant starch) that you eat, which then feeds bacteria already living in your gut.

A probiotic is, per ISAPP's 2014 consensus statement (building on the earlier FAO/WHO definition), "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host" — specific, named strains of live bacteria or yeast added directly to the gut via a supplement or fermented food.

In short: prebiotics feed the bacteria you already have; probiotics add new bacteria on top. Both are real, defined categories — but as the sections below show, the strength of evidence behind them differs a lot depending on the specific claim being made.

Mechanism: fermentable fibers like inulin and FOS pass undigested into the colon, where resident bacteria ferment them into short-chain fatty acids (acetate, propionate, butyrate) and, in the process, tend to increase populations of specific bacterial groups — most consistently Bifidobacterium.

Evidence: a randomized controlled trial of inulin-type fructans in adults with type 2 diabetes found significant increases in fecal short-chain fatty acid concentrations and shifts in gut microbiota composition, including a bifidogenic effect, compared to placebo over the supplementation period.

Read the inulin-type fructans RCT →

This kind of compositional shift — more short-chain-fatty-acid-producing bacteria, higher SCFA output — is one of the better-replicated findings in this space. It's a real, measurable change in gut microbiome activity. What's less settled is how directly and consistently that compositional shift translates into a specific clinical outcome (weight, blood sugar, immune markers) for a general, healthy population — the mechanistic evidence is stronger than the downstream-outcome evidence.

Mechanism: live strains are meant to transiently colonize or pass through the gut, competing with less helpful microbes, producing metabolites, and interacting with the gut immune system — though effects vary considerably by genus, species, and even the specific strain used.

The evidence is strain-specific and condition-specific — not a blanket "probiotics work" story. McFarland LV, Evans CT, Goldstein EJC, "Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis," Frontiers in Medicine, 2018, found strong evidence that probiotic efficacy is both strain- and disease-specific — pooling different strains together in reviews can produce misleadingly generalized conclusions, and a benefit shown for one strain doesn't reliably transfer to a different strain of the same species.

Read the strain-specificity meta-analysis →

Where the evidence is comparatively solid: antibiotic-associated diarrhea prevention. Blaabjerg S, Artzi DM, Aabenhus R, "Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients — A Systematic Review and Meta-Analysis," Antibiotics, 2017 — pooling 17 randomized controlled trials (3,631 participants), probiotic use was associated with a statistically significant reduction in antibiotic-associated diarrhea (RR 0.49, 95% CI 0.36–0.66), with no significant increase in adverse events across the pooled trials. Follow-up work on strain specificity has narrowed this further — the clearest adult AAD benefit has been demonstrated for a handful of specific strains and strain combinations, not the category as a whole.

Read the antibiotic-associated diarrhea meta-analysis →

Where the evidence is thinner: broad "gut health" or general wellness claims on commercial probiotic labels frequently name a genus or species without specifying — or without matching — the exact strain that was actually studied in a clinical trial. Per the strain-specificity findings above, that's a meaningful gap: a strain untested for a given condition isn't the same product, evidence-wise, as the strain that was tested, even if the label lists the same species.

For healthy people, probiotics are generally considered low-risk — the gut barrier and immune system normally keep the added microorganisms from causing problems. That changes for immunocompromised people (including those undergoing chemotherapy or with hematologic malignancies), critically ill patients, and anyone with a central venous catheter: case reports link probiotic use in these groups to rare but serious bloodstream infections (bacteremia or fungemia), and clinical guidance specifically advises against certain probiotics (such as Saccharomyces boulardii) in immunocompromised or critically ill patients. Probiotic supplements are also regulated as dietary supplements, not drugs, so they don't undergo the same premarket safety and efficacy review. Prebiotic fibers carry the same caution as fiber in general — start low and increase gradually to avoid gas and bloating.

Prebiotics are a subset of dietary fiber specifically — see our Fiber page for the broader intake targets, soluble/insoluble mechanisms, and cardiovascular evidence that apply to fiber intake as a whole.